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Abstract. We measured the levels of interferon alpha (IFNa) in the sera of Thai children
hospitalized with dengue hemorrhagic fever (DHF) or dengue fever (DF) to examine the
role of IFNa in dengue virus infections of humans. The percentage of patients who had
detectable levels of IFNa ( 3 U/ml) was higher in patients with DHF (80%, P < 0.001)
and in patients with DF (60%, P < 0.001) than in healthy Thai children (7%). The levels
of IFNa were higher in patients with DHF and in patients with DF on the first few days
after the onset of fever than in healthy Thai children. The average levels of IFNa in patients
with DHF were high two days before defervescence, decreasing gradually until the day of
defervescence. There was a subset of patients with DHF who had increasing levels of IFNa
after defervescence. However, the levels of IFNa in patients with DF were not high after
fever subsided. The levels of IFNa were not different among children with DHF grades 1,
2 and 3. Among patients with DHF, T lymphocytes were activated to a higher degree in
high IFNa producers than in low IFNa producers. These results indicate that similarly
high levels of IFNa are produced in vivo during the acute stages of DHF and DF, and that
high levels of IFNa remain after fever subsides in some patients with DHF, but not in
patients with DF.
Dengue virus infections are a major cause of
morbidity in tropical and subtropical areas of the
world. Dengue virus infection causes two forms
of illness; dengue fever (DF) and dengue hem
orrhagic fever (DHF).' Dengue fever is a self
limited febrile disease, while DHF is a severe,
sometimes fatal syndrome characterized by
hemorrhagic manifestations and plasma leakage
that may lead to shock. The mechanisms of re
covery from dengue virus infection and the
pathogenesis of DHF are not clearly understood.
We have reported that dengue virusâ€”infected
cells are lysed by natural killer cells and by an
tibody-dependent cell-mediated cytotoxicity.2 We
have also reported the presence of dengue virus
specific, cytotoxic T lymphocytes that lyse den
gue virus-infected cells in a major histocompat
ibility complexâ€”restricted fashion.3'4 Antibodies
to dengue viruses neutralize the virus and can
prevent infection.5 These immune responses may
be important in prevention and recovery from
dengue virus infection, and may contribute to
the pathogenesis of DHF. We have detected
higher levels of activation of T lymphocytes in
patients with DHF than in those with DF, and
have hypothesized that dengue virus-specific T
cells play an important role in the pathogenesis
of DHF.6 Another host defense mechanism that
should be considered is interferon (IFN) pro
duction. It has been reported that IFN has an
important role in controlling viral infections.7
We have reported that dengue virusâ€”infected
monocytes produce IFNa,8 and that dengue vi
rus-infected monocytes also induced IFNa from
autologous nonimmune lymphocytes.9 Interfer
on alpha produced by these two mechanisms
protects uninfected monocytes from dengue vi
rus infection.8'9 In addition to antiviral effects,
IFNa has immunoregulating effects on natural
killer cells,'Â° T cells,â€• and B cells.'2 Thus, IFNa
may have important regulatory roles in the
pathogenesis of DHF.
In this study, we examined the levels of IFNa
in the sera of patients hospitalized with DHF
and those hospitalized with DF, and compared
those data with levels of IFNa in the sera of
healthy Thai children. The results show that sig
nificantly higher levels of IFNa are detected in
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the sera of patients with DHF or DF before and
on the day of defervescence than in the sera of
healthy Thai children. The average levels of IFNa
are still high 7â€”19days after defervescence in
some patients with DHF, while the levels are not
high after fever subsides in patients with DF.
PATIENTS AND METHODS
Patientsand normal controldonors
We examined serial serum specimens from 45
children with an age range of5â€”l4years (35 chil
dren with DHF and 10 children with DF) who
were hospitalized with dengue virus infections
during 1987 and 1988 in the hemorrhagic fever
unit of the Bangkok Children's Hospital. These
sera were obtained from a randomly selected
group ofsequential patients whose sera were sub
mitted for evaluation of suspected dengue virus
infection. Specimens were collected for diagnos
tic studies by nurses participating in the project
within 24 hr of admission to the hospital and
daily until discharge; a convalescent specimen
was also collected from each child 7â€”10days after
hospital admission. A portion ofeach specimen
was kept at â€”70Â°Cand was available for analysis.
To study healthy children (controls), we ex
amined aliquots of single serum specimens from
a random sample of healthy Thai children (n =
30, age range 6â€”11years) obtained in an earlier
cross-sectional study of hepatitis antibody prev
alence. These sera were stored at â€”70Â°Cfrom
the time of collection until assay.
A diagnosis of dengue hemorrhagic fever was
assigned to children with dengue infection when
the level of thrombocytopenia and signs of hem
orrhage and plasma leakage met established cii
teria.'3 Hospitalized patients were followed with
frequent determinations of blood pressure and
pulse. Measurements of hematocrit in blood ob
tained by fingerprick were recorded at 3â€”4-hr
intervals, according to vital signs. Physical find
ings of plasma leakage (pleural effusion, ascites)
and indications of circulatory collapse (cyanosis,
cold extremities) were recorded in the clinical
record. Whenever feasible, chest radiographs in
cluding decubitus views were performed to doc
ument the presence of pleural fluid. Hemorrhagic
manifestations (positive tourniquet test result for
capillary fragility, skin hemorrhages, epistaxis,
and gingival, gastrointestinal, or urinary tract
hemorrhage) were also recorded. Without knowl
edge ofIFNa levels, three ofthe investigators (S.
N., B. L. I., and A. N.) reviewed every record,
including radiographs, to assign a diagnosis. Cases
ofdengue infection that did not meet the World
Health Organization (WHO)definition of DHF'3
were classified as dengue fever (n = 10). The
severity of cases of DHF was categorized ac
cording to the WHO grading scheme:'3 grade 1
= fever accompanied by nonspecific constitu
tional symptoms (the only hemorrhagic mani
festation is a positive tourniquet test result); grade
2 = spontaneous bleeding, in addition to the
manifestations ofgrade 1 patients, usually in the
form of skin and/or other hemorrhages; grade 3
= circulatory failure manifested by rapid and
weak pulse, narrowing of pulse pressure (@ 20
mm Hg) or hypotension, with the presence of
cold, clammy skin and restlessness.
Dengue virus infections were confirmed by the
detection of antiviral 1gM or increasing titers of
antiviral hemagglutination-inhibiting antibodies
or by virus isolation from plasma, according to
previously published@ Cases of dengue
infection were categorized as secondary (dengue
infection in a child previously infected with a
heterologous flavivirus) or primary (no prior fla
vivirus infection) according to the presence or
absence of an anamnestic antiflavivirus antibody
response.'4. Table 1 shows the age and sex dis
tribution and serologic data of patients and con
trol subjects.
AssayforIFNa
The levels of IFNa were measured in sand
wich-type enzyme-linked immunosorbent assays
(ELISA) as previously described.'5â€•6 Fifty mi
croliters of pwified monoclonal antibodies to hu
man IFNa'6' â€˜@â€˜at a concentration of 10 Mg/ml
was coated on U-bottomed wells of polyvinyl
chloride microtiter plates (Dynatech, McLean,
VA) for 1 hr at 37Â°C.The remaining sites in the
wells were blocked overnight with 150 @lof
blocking buffer (2% bovine serum albumin
phosphate-buffered saline [PBS]) at 4Â°C.Excess
antibodies and blocking buffer were removed and
the wells were washed four times with 0.05%
Tween 20-PBS. Following the last wash, serial
dilutions of human IFNa standard (first inter
national reference preparation for human leu
kocyte interferon, 69/19, 5,000 lU/ampule) or
serum samples were added (50 Ml/well) and in
cubated at 37Â°C for 1 hr. The wells were then
SubjectaNo.SexAverage
Â±SD, years
(range)Dengueser logyMaleFemalePrimarySecondaryDHF
DF
Healthy children35
10
3019
6
1316
4
179.1
Â±2.9(5â€”14)
9.9 Â±2.9 (5â€”14)
7.9Â±1.4(6-11)3
4
032
6
0DHF
â€”denguehemorrhagicfever DF â€”dengue fever.
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Age and sex distribution and dengue antibody responses of the patients and control subjects8
washed four times with Tween 20-PBS. Horse
radish peroxidaseâ€”linked calf antihuman IFNa
immunoglobulin at a 1:4,000 dilution in 10%
fetal calfserum-PBS (50 ML'well) was added and
incubated for 30 mm at 37Â°C.Finally, the wells
were washed three times with Tween 20-PBS and
twice with 0. 1 M citrate phosphate buffer, pH
5.0, followed by the addition of o-phenylenedi
amine substrate at a concentration of 1 mg/ml
in 0.1 M citrate phosphate buffer containing
0.006% hydrogen peroxide. Color was developed
in the dark for 30 min at room temperature and
the reaction was terminated by the addition of
50 zlof! M H2SO4 to each well. Optical densities
were read at 492 nm in a Titertek Multiskan plate
reader (Flow Laboratories, McLean, VA). The
levels of IFNa in serum samples were interpo
lated from the IFNa standard calibration curve,
using the 1st international reference preparation
for human leukocyte interferon, 69/19, 5,000 IU/
ampule. The detection limit of the assay was 3
IU/ml.
Assays for soluble interleukin-2 receptor (sIL-2R)
and soluble antigens of CD4 and CD8 cells (sCD4
and sCD8)
The levels of sIL-2R, sCD4, and sCD8 were
measured using commercial ELISAs (cell-free
IL-2 receptor test kit, cell-free CD4 test kit, and
cell-free T8 test kit, respectively; T Cell Sciences,
Inc., Cambridge, MA). The results are expressed
as units per milliliter based on the standard pro
vided by the manufacturer.
AssayforIL-2
The levels of IL-2 were measured using a com
mercial ELISA (Intertest-2; Genzyme, Boston,
MA). The results are expressed as units per mil
liliter.
AssayforIFN'y
Levels ofIFN7 were determined because they
are one of the markers that reflect T cell acti
vation in patients with DHF. They were mea
sured using a commercial radioimmunoassay
(Centocor Diagnostics, Malvern, PA). The re
sults are expressed as international units per mil
liliter.
Statistical analysis
Differences between values were examined us
ing the Student's t-test and the chi-square test.
The levels ofIFNa were log-transformed for sta
tistical analysis. Undetectable levels ofIFNa (<
3 IU/ml) were considered to be 1 IU/ml for log
transformation. Differences yielding P values of
0.05 were regarded as significant.
RESULTS
Levels of IFNa in the sera of patients with DHF
orDF
The sera from patients with DHF or DF were
examined for levels of IFNa. These levels were
then compared with levels in the sera of healthy
Thai children. The day of onset of fever was
defined as day 0 (Figure 1). Interferon alpha was
detected in 80% (28 of 35) of the patients with
DHF and in 60% (6 of 10) of the patients with
DF during days 1â€”20after the onset of fever,
while only 7% (2 of 30) of the sera of healthy
Thaichildrencontained etectablelevelsofIFNa
(P < 0.001 for DHF and P < 0.001 for DF, by
chi-square test) (Figure 1).
The levels of IFNa in the sera of patients with
acute DHF were higher than those in the sera of
healthy Thai children (P < 0.001 on day 3 and
P < 0.05 on days 2 and 4), and the levels were
also high on days 6â€”20after onset of fever (P <
0.05 ondays6,P< 0.O2onday7,andP<
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Days After Onset of Fever
Fioua@ 1. Levels of interferon alpha (IFNcr) in the sera of patients with dengue hemorrhagic fever (DHF)
and those with dengue fever (DF) on days after the onset of fever. The geometric mean titers (bars) of IFNa
were 1.39 IU/ml (n = 30) in healthy Thai children, 7.28 lU/mi (n = 3) on day 2, 9.14 lU/mi (n = 12)on day
3, 3.10 lU/mi (n = 20) on day 4, 2.37 lU/mi (n = 22) on day 5, 3.49 lU/mi (n = 20) on day 6, 4.65 lU/mi (n
= 12) on day 7, and 4.68 lU/mi (n = 25) on days 10â€”20 in the sera of patients with DHF, and 6.47 IU/ml (n
= 4) on day 1, 2.94 lU/mi (n = 4) on day 2, 8.95 lU/mi (n = 6) on day 3, 1 lU/mi (n = 5) on day 4, 1.86
lU/mi (n = 4) on day 5,@ 1 lU/mi (n = 4) on days 6â€”7,and 1.73 lU/mi (n = 4) on days 10â€”20in the sera of
patients with DF. 0= primary, hospitalized;. = secondary, hospitalized; A = healthy Thai children. Levels of
IFNa were compared with the levels in the healthy Thai children by Student's t-test after log-transformation.
*P < 0.05; @P< 0.01; @.P< 0.001.
IFNa did not change during days 0â€”19.The lev
els of IFNa in patients with DF were high one
day before and on the day of defervescence, but
these levels were not high after the fever subsid
ed.
Changes intheserum levelsofIFNa ineach
patientwithDHF
We attempted to determine the changes in the
levels of IFNa in each patient during the course
of DHF. Patients with DHF were separated into
two groups, based on the levels of IFNa on days
7â€”12afterdefervescence:11 subjectswho had
detectablelevelsof IFNa (> 3 lU/mi) (Figure
3A) and 10 patients who did not have detectable
levels of IFNa (Figure 3B). Most of the patients
who had detectable levels of IFNa on days 7â€”12
after defervescence had lower levels of IFNa dur
0.005 on days 10â€”20).The levels of IFNa in the
sera of patients with acute DF were higher than
those in the sera of healthy Thai children (P <
0.05 on day 1 and P < 0.005 on day 3); however,
the levels were not high on days 4â€”20after onset
of fever (Figure 1).
Levels of IFNa in the sera of patients before and
aftertheday ofdefervescence
The timing of plasma leakage in patients with
DHF is predictable; circulatory collapse occurs
as fever subsides. Therefore, we evaluated the
levels of IFNa in the patients with DHF or DF,
defining the day ofdefervescence as day 0 (Figure
2).The averagelevelsof IFNa in patientswith
DHF were highest two days before deferves
cence, and decreased gradually until the day of
defervescence. However, the average levels of
**
Patients with DF Patients with DHF
226 KURANE AND OTHERS
-10123410-13 i0i237:910-19H@
** * ** * ** * Children
Patients with DF Patients with DHF
Days Before or After Defervescence
Fiouxe 2. Levels of interferon alpha (IFNa) in the sera of patients with dengue hemorrhagic fever (DHF)
and those with dengue fever (DF) on days before or after defervescence. The day of defervescence is defined as
day 0. The geometric mean titers (bars) of IFNa were 1.39 lU/mi (n = 30) in healthy Thai children, 14.4 IU/
ml (n= 2)on day â€”2,4.68lU/mi(n= 13)on dayâ€”1,3.36lU/mi(n= 14)on day0,3.97lU/mi(n= 27)on
day 1, 3.30 lU/mi (n = 20) on day 2, 2.59 lU/mi (n = 11) on day 3, 4.68 lU/mi (n = 16) on days 7â€”9,and
5.11 lU/mi (n = 7) on days 10â€”19in the sera of patients with DHF, and 41.9 lU/mi (n = 2) on day â€”1,4.52
lU/mi (n = 6) on day 0, 4.07 lU/mi (n = 6) on day 1, 1 lU/mi (n = 4) on day 2, 2.29 lU/mi (n = 3) on day
3,@ 1 lU/mi (n = 3) on day 4, and 1.73 lU/mi (n = 4) on days 10â€”13in the scm of the patients with DF. 0 =
primary, hospitalized; S = secondary, hospitalized; A = healthy Thai children. Levels of IFNa were compared
with the levels in the healthy Thai children by Student's 1-test after log-transformation. P < 0.05; @P< 0.01;
5P < 0.001.
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ing days 0-4 after defervescence (Figure 3A). Most
of the patients who did not have detectable levels
of IFNa during days 7â€”12had detectable levels
of IFNa during days 0-4 after defervescence (Fig
ure 3B). It is of interest that high levels of IFNa
were detected on days 7â€”19after defervescence
in some patients who had lower levels of IFNa
during the early stages of illness.
Comparison ofthelevelsofIFNa among patients
withDHF grades1,2,and 3
The levels of IFNa were compared among pa
tients with DHF grades 1, 2, and 3 from one day
before defervescence to nine days after defer
vescence (Figure 4). They did not differ among
these three groups.
Levels of Tcell activation in high IFNa producers
and low IFNa producers amongpatients with DHF
We have previously reported that T lympho
cytes are highly activated in patients with DHF
by determining the high serum levels of sIL-2R,
sCD4, sCD8, IL-2, and IFN7.6 The levels of these
soluble cell-surface proteins and lymphokines
were compared between high IFNa producers
and low IFNa producers among patients with
DHF during days 2â€”8after onset of fever (Table
2). Patients who had serum IFNa levels higher
than 30 IU/ml at least one day during days 2â€”8
after onset of fever were defined as high IFNa
producers. Patients who did not have serum IFN
levels higher than 10 IU/ml during this period
were defined as low IFNa producers. The levels
MarkersHigh
IFNa producers(>30 lU/mI)Low IFNa producers(<10lU/mi)Titers,
U/mI
(mean Â±SD)No.
of
samplesTiters,
U/mi
(mean Â±SD)No.
of
samplesPsIL-2R5,921
Â±78142,079 Â±2617<0.001sCD448.4
Â±9.5531.2 Â±3.09<0.ijsCD81,270
Â±22571,355 Â±i649<0.8tIL-2
(log0)1.654 Â±0.37271.391 Â±0.2729<0.8tIFNy
(log,0)0.200 Â±0.2447â€”0.201 Â±0.1869<0.5t
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ofslL-2R were significantly higher in high IFNa
producers than in low IFNa producers (P <
0.001). The levels ofsCD4, IL-2, and IFN@ywere
higher in high IFNa producers than in low IFNa
producers, but the differences were not statisti
cally significant. These results suggest that T lym
phocytes are activated to a higher degree in high
IFNa producers than in low IFNa producers.
DISCUSSION
In this study, we examined the levels of IFNa
in the sera ofpatients hospitalized with DHF or
DF. The percentage of subjects who had detect
able levels of IFNa and the levels of IFNa on
days 1â€”3after the onset of fever were higher in
patients with DHF or DF than in healthy Thai
children. These results indicate that high levels
of IFNa are produced in vivo during the acute
stage of dengue virus infection.
The average levels of IFNa in the sera of pa
tients with DHF were also high on days 4â€”20
after the onset of fever, while the levels of IFNa
in the sera of patients with DF were not high
after day 4. The levels of IFNa in patients with
DHF were high two days before defervescence
and decreased gradually until the day of defer
vescence, defined as day 0. The average levels of
IFNa did not change between days 0 and 19.
Approximately half of the patients with DHF
had detectable levels of IFNa on days 7â€”19after
defervescence, and the levels of IFNa were high
er on days 7â€”19than on days 0â€”4after defer
vescence in these patients. In contrast, the av
erage levels of IFNa in patients with DF were
high one day before defervescence and on the
TAaut 2
Levels of soluble cell-surface proteins and lymphokines in high interferon alpha (IFN a) producers and low IFNa
producers among the patients with dengue hemorrhagic fryer (DHF)
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Fiouxn 3. Changes in the levelsofinterferon alpha
(IFNa) in each patient with dengue hemorrhagic fever
during the course of illness. Each line represents the
changes in thelevels ofIFNa in one patient. A, patients
who had detectable levels of IFNa ( 3 lU/mi) in their
sera on days 7â€”12after defervescence. B, patients who
did not have detectable levels of IFNa on days 7â€”12
after defervescence.
Patienta with DHF who had serum IFNa levels higher than 30 lU/mi at leaat one day during days 2â€”Safter the onset of fever were defined aa
high IFNa producers. Patients with DHF who did not have serum IFNa levels higher than 10 lU/mi during days 2â€”Swere defined as low IFNa
responders. The highest levels of soluble interleukin-2 receptor (sIL-2R), sCD4, sCD8, IL-2, and lFN@during days 2-S after the onset of fever were
compared between high IFNa producers and low IFNa producers by Student's i-test. The titers of IL-2 and IFN-y were log-transformed for analysis.
t Not significant.
0 4 8
Days Beforeor After
Defervescence
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FlouxE4. Levelsofinterferonalpha(IFNa)inpatientswithdenguehemorrhagicfevergrades1,2,and 3.
Levels are shown as mean titers + SEM. Values in parentheses above the bars are the number of samples.
Hatchedbars= grade1;dottedbars= grade2;solidbars= grade3.
-1 0 1 2 3 7-9
day of defervescence, but decreased after the fe
ver subsided.
The origins of IFNa detected in the sera are
not clear. We have reported that dengue virus
infected monocytes produce IFNa ,8 and that
these dengue virus-infected monocytes induce
IFNa from autologous HLA-DR+ lympho
cytes.@We assume thattheIFNa detectedinthese
childrenwas releasedby these mechanisms;
however, other mechanisms of IFNa production
cannot be ruled out. The finding that some pa
tients with DHF had increasing levels of IFNa
during convalescence may suggest that the in
fection was not completely eradicated even 7â€”
19 days after defervescence. We did not find in
creasing levels of IFNa after defervescence in
patients with DF, which possibly indicates that
the termination of virus replication is more rap
idly achieved in DF.
Burke and Morrili reported that high levels of
IFNa were detected in the plasma and cerebro
spinal fluids of patients with Japanese enceph
alitis, and that there was a positive correlation
between the levels of IFNa in cerebrospinal flu
ids and in fatal outcome)8 They interpreted that
the correlation between high IFNa levels and
fatal outcome reflects a higher degree of virus
replication in the brain. Our observation that
similar levels of IFNa were detected in patients
with DHF and in patients with DF atleast during
the early stage of illness suggests that the degree
ofinfection may be similarbetween patients with
DHF and patients with DF whose symptoms are
severe enough to require hospitalization. The pa
tients with DF examined in this study were hos
pitalized and they had more severe symptoms
than many children with DF who usually do not
need to be hospitalized. Therefore, the sera of
nonhospitalized children with less severe DF need
to be examined in a future study.
Among patients with DHF, the levels of sIL
2R, sCD4, IL-2, and IFN'y were higher in sub
jects who had high serum levels of IFNa than in
those who had low serum levels of IFNa, al
though the differences were not statistically sig
nificant for sCD4, IL-2, and IFN'y. These results
suggest that the levels of T cell activation are
higher in high IFNa producers than in low IFNa
producers. This difference may reflect the differ
ence in the levels of dengue virus infections; i.e.,
higher levels of dengue virus replication induce
higher levels of IFNa and also induce higher lev
els of T cell activation.
Although this study does not suggest a direct
role of IFNa in the pathogenesis of DHF, it is
possible that IFNa has an important role in the
229IFNa IN DENGUE VIRUS INFECTION
control ofdengue virus infections. Thus, the role
ofIFNa in recovery from dengue virus infection
is an important subject for further investigation.
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